SCHEMBL14725978

SCHEMBL14725978

COc1cccc(-c2nc(O)c3cncn3n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.47
NR1H3 Q13133 3/20 0.47
DYRK1A Q13627 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
BRD9 Q9H8M2 1/20 0.46
MAPT P10636 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
RAB9A P51151 4/20 0.45
NPC1 O15118 3/20 0.45
ALDH1A1 P00352 2/20 0.45
TP53 P04637 3/20 0.44
CYP1A2 P05177 3/20 0.44
CYP3A4 P08684 3/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C19 P33261 2/20 0.44
MAPK1 P28482 2/20 0.44
LMNA P02545 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP2C9 P11712 2/20 0.43
RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18599844 0.86 NR1H2 (0.48) NR1H2NR1H3DYRK1ACLK4BRD9
SCHEMBL14725975 0.85 NR1H2 (0.47) NR1H2NR1H3DYRK1ACLK4BRD9
SCHEMBL14725977 0.77 PIK3CA (0.52) CLK4ALDH1A1TP53CYP1A2CYP3A4
SCHEMBL18599848 0.76 CRHR1 (0.42) NR1H2NR1H3DYRK1ACLK4BRD9
SCHEMBL18343119 0.69 CYP1A2 (0.55) DYRK1ACLK4MAPTSMN1; SMN2RAB9A
SCHEMBL27807278 0.68 DYRK1A (0.69) NR1H2NR1H3DYRK1ACLK4MAPT
SCHEMBL9104238 0.68 DYRK1A (0.47) NR1H2NR1H3DYRK1ACLK4MAPT
SCHEMBL11781393 0.68 MEN1 (0.52) NR1H2NR1H3DYRK1ACLK4ALDH1A1
SCHEMBL9105777 0.68 AHR (0.59) NR1H2NR1H3DYRK1ACLK4MAPT
SCHEMBL30393103 0.68 CYP1A2 (0.53) NR1H2NR1H3DYRK1ACLK4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053371-A1 INHIBITORS OF PI3 KINASE PIK3CA, MTOR, PIK3C2A NR1H2 2181/4885NR1H3 1685/4885DYRK1A 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.